Department of Head and Neck Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Icahn School of Medicine at Mount Sinai, New York, NY.
Int Forum Allergy Rhinol. 2019 Mar;9(3):322-329. doi: 10.1002/alr.22241. Epub 2018 Nov 23.
Transsphenoidal pituitary surgery has evolved into a safe procedure with shorter hospitalizations, yet unplanned readmissions remain a quality measure for which there is a paucity of data. We sought to examine rates, timing, etiologic factors, and costs surrounding readmission after transsphenoidal pituitary surgery.
The Nationwide Readmissions Database (NRD) was queried for patients who underwent transsphenoidal pituitary between January 2013 and November 2013. Patient, procedure, admission, and hospital-level characteristics were compared for patients with and without unplanned 30-day readmission. Multivariate logistic regression was used to identify readmission predictors. A total of 8546 patients were included in this retrospective study.
A total of 8546 patients with a median age of 54 years and female predominance were identified, with 742 patients experiencing at least 1 unplanned readmission within 30 days of index admission. Hypertension, hypothyroidism, diabetes, and obesity were common comorbidities among readmitted patients. Readmission was most frequently because of nervous system complications, followed by neurohypophyseal or electrolyte disorders, cerebrospinal fluid leak, hemorrhage, and meningitis. Median length and cost of stay of index admission was greater in the readmission group (p < 0.001). Fluid and electrolyte disorders as well as neurologic disease (most commonly epilepsy or convulsions) present on initial admission were predictive of length of initial stay and readmission (p < 0.001). Median readmission cost was $7723 and was expected to occur within 7 days.
Approximately 8.7% of patients undergoing transsphenoidal pituitary surgery experience an unplanned readmission within 30 days of discharge. Risk factors identified should be considered to reduce preventable readmissions and identify medically complex patients.
经蝶窦垂体手术已发展为一种安全的手术,其住院时间更短,但计划外再入院仍是衡量手术质量的一个指标,目前这方面的数据还很缺乏。我们旨在研究经蝶窦垂体手术后再入院的发生率、时间、病因因素和费用。
在 2013 年 1 月至 2013 年 11 月期间,我们在全国再入院数据库(NRD)中查询了接受经蝶窦垂体手术的患者。对比了有和无计划内 30 天再入院患者的患者、手术、入院和医院水平特征。采用多变量逻辑回归确定再入院预测因素。本回顾性研究共纳入 8546 例患者,中位年龄为 54 岁,女性居多,874 例患者在索引入院后 30 天内至少发生 1 次计划外再入院。高血压、甲状腺功能减退症、糖尿病和肥胖症是再入院患者常见的合并症。再入院的主要原因是神经系统并发症,其次是神经垂体或电解质紊乱、脑脊液漏、出血和脑膜炎。再入院组的索引入院中位住院时间和费用均较高(p<0.001)。入院时存在液体和电解质紊乱以及神经系统疾病(最常见的是癫痫或抽搐)与初始住院时间和再入院相关(p<0.001)。再入院的中位费用为 7723 美元,预计将在 7 天内发生。
大约 8.7%接受经蝶窦垂体手术的患者在出院后 30 天内经历了计划外再入院。应考虑确定的风险因素,以减少可预防的再入院,并识别医疗复杂的患者。